Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment

Core Insights - Cigna Group (CI) will start covering RhinAer, a minimally invasive treatment for chronic rhinitis, effective September 15, 2025, providing access to over 15 million members [1][9] - RhinAer, developed by Aerin Medical, uses temperature-controlled radiofrequency technology and is incisionless, requiring only local anesthesia [2][9] - The decision to cover RhinAer is based on over 20 peer-reviewed studies and three years of outcome data, confirming its clinical effectiveness [3][9] Company Positioning - Cigna's inclusion of RhinAer in its coverage reflects its commitment to minimally invasive and evidence-based treatments, enhancing its value in the healthcare market [4] - The company aims to reduce the reliance on invasive procedures and long-term medications, aligning with its focus on member-centered care and cost containment [4] - In 2024, Cigna delivered over 8 million prescriptions to more than a million patients, showcasing its operational capabilities [5] Stock Performance - Over the past year, Cigna's shares have increased by 0.3%, contrasting with a 29.7% decline in the industry [8]